# Antitoxin Levels in Botulism Patients Treated with Trivalent Equine Botulism Antitoxin to Toxin Types A, B, and E

Charles H. Hatheway, John D. Snyder, Jerry E. Seals, Timm A. Edell and George E. Lewis Jr.
The Journal of Infectious Diseases
Vol. 150, No. 3 (Sep., 1984), pp. 407-412
Stable URL: http://www.jstor.org/stable/30131554
Page Count: 6

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

Preview not available

## Abstract

Serum levels of equine-botulism antitoxin to toxin types A, B, and E were measured in four type-A botulism patients who had received equine-botulism antitoxin. High circulating levels capable of neutralizing in excess of $1 \times 10^{8}$, $9 \times 10^{7}$, and $6 \times 10^{6}$ 50% mouse lethal doses of toxin of types A, B, and E, respectively, were detected. There was little depletion of type-A antitoxin even though two of the patients had circulating type-A toxin before treatment. The half-life for antitoxin persistence for one patient was calculated as being 6.5, 7.6, and 5.3 days for antitoxin types A, B, and E, respectively. Antitoxin levels were not proportionate to the amount (range, 2-4 vials) injected and did not appear to be affected by whether the route of administration was iv or im. Peak serum levels of antitoxin were 10-1,000 times higher than amounts needed to neutralize the toxin measured in the serum of these and other patients with botulism.

• 407
• 408
• 409
• 410
• 411
• 412